-

05:03:39 PM

SONN Stock News

SONN - Sonnet BioTherapeutics Holdings Inc

10/04/22 8:00 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet BioTherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on

RHEA-AI

neutral

09/26/22 8:00 AM

Nasdaq : SONN

managementlow float

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC) The BAC will advise the company on business

RHEA-AI

very positive

09/21/22 8:00 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

RHEA-AI

very positive

09/16/22 8:30 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-14 reverse stock split of its outstanding common

RHEA-AI

neutral

08/15/22 4:05 PM

Nasdaq : SONN

earningslow float

Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update

Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors Positive preclinical data of SON-1010 combined with anti-PD1 Checkpoint Inhibition Subsequent Events During The Fiscal Year 2022 Fourth Quarter Initiation of clinical trial of SON-080 in

RHEA-AI

positive

07/22/22 7:00 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

RHEA-AI

neutral

07/21/22 7:30 AM

Nasdaq : SONN

clinical triallow float

Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Holdings,

RHEA-AI

very positive

06/09/22 7:00 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-F H AB) and a commercially available anti-PD1 antibody Combination of SON-1010 with anti-PD1 increased survival rate These data will guide future combination study designs with SON-1010 and checkpoint

RHEA-AI

very positive

06/02/22 9:25 AM

Nasdaq : SONN

low float

Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today announced that the Company's 2022 Annual Meeting of Stockholders, on June 2, 2022 at 9:00

RHEA-AI

neutral

05/10/22 8:15 AM

Nasdaq : SONN

earningslow float

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, SON-1210, and SON-1410 presented at the 2022 AACR Annual Meeting Preclinical development of additional F H AB pipeline

RHEA-AI

very positive

SONN Data

IndustryFood Service Contractors
Websitesonnetbio.com
CeoMichael Pruitt
Security nameSonnet BioTherapeutics Holdings Inc
Issue typecs
SectorAccommodation and Food Services
Sic code5812
Employees8
Tags
- Consumer Services
- Restaurants
- Health Technology
- Biotechnology
- Accommodation and Food Services
- Food Service Contractors
Address100 Overlook Center
Address2Suite 102
StateNew Jersey
CityPrinceton
Zip08540
CountryUS
Phone16093752227

About Sonnet BioTherapeutics Holdings Inc

Founded in 2011, Sonnet Biotherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and 'hitch-hikes' on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.